An incident that tied a compounded drug solution to three deaths and eight acute illnesses has captured the attention of both the media and the many pharmacists who regularly compound critical care drug products for hospital use.

The Food & Drug Administration recently issued letters to three pharmacies warning them to "stop manufacturing and distributing thousands of doses of compounded, unapproved inhalation drugs nationwide." The three named companies, RoTech Healthcare, CCS Medical, and Reliant Pharmacy Services, were all warned that if they did not comply, they risked injunctions and the possible seizure of their products in question.

The U.S. Senate, following in the footsteps of the House, has introduced a resolution urging FDA to lift its restrictions on the use of estriol in bioidentical hormone preparation.

To better ward off blows by the FDA to compounding pharmacists, IACP has established a satellite office at NCPA's headquarters.

The Centers for Medicare & Medicaid Services has issued an FAQ that explains about the use of a non-NPI for prescribers who are not covered entities.

An expert contends that pharmacists should learn about pharmacogenetics and get into the field now

Since three steroids have a high potential for drug abuse and trafficking, the Drug Enforcement Administration wants to classify them as Schedule III controlled substances.

The infusion provider InfuScience has added two pharmacies in Florida

Insmed has received a questionnaire from House of Representatives' Subcommittee on Health on develdoping legislation to establish a follow-on biologics regulatory pathway.